By Ellen Foster Licking
In late December, AstraZeneca PLC signed a licensing deal worth up to $1 billion dollars with the Georgia-based biotech...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?
Anatomy of a Deal: Inside the AstraZeneca/ AtheroGenics Agreement
AstraZeneca agreed in late December to pay AtheroGenics a $50 million upfront fee and another $950 million in regulatory and commercial milestones for the biotech's VCAM-I inhibitor AGI-1067. Though many heralded the deal as a win-win for both companies, a closer analysis shows that AtheroGenics continues to shoulder the development costs--and risks--of the Phase III product.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
In Partnership with Cerba Research
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
• By
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.